Literature DB >> 6265566

Cytolytic IgM antibody to cytomegalovirus in primary cytomegalovirus infection in humans.

R F Betts, S G Schmidt.   

Abstract

Suspensions of cytomegalovirus (CMV)-infected human foreskin fibroblasts were used to measure cytolytic antibody (CyA) to CMV in serum by a 51Cr release assay. CyA was associated with IgM but not with IgG antibody to CMV, required rabbit or human complement, and was directed at a surface antigen. CyA was detectable for one to three months in the sera of 16 patients with community-acquired CMV infection and in the sera of 20 of 22 renal transplant recipients with primary CMV infection. CyA was found less frequently in the sera of renal transplant recipients with reactivated CMV infection and occurred almost exclusively when the donor was seropositive for CMV. One individual, unlike many patients with CyA, was free of symptoms. Sera from patients with either rheumatoid factor-positive arthritis or heterophil-positive infectious mononucleosis and from 70 of 71 control patients with other types of antibody to CMV yielded no 51Cr release.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6265566     DOI: 10.1093/infdis/143.6.821

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Quantitative measurement of cytomegalovirus-specific IgG and IgM antibodies in relation to cytomegalovirus antigenaemia and disease activity in kidney recipients with an active cytomegalovirus infection.

Authors:  M Van der Giessen; A P van den Berg; W van der Bij; S Postma; W J van Son; T H The
Journal:  Clin Exp Immunol       Date:  1990-04       Impact factor: 4.330

2.  Cytomegalovirus early and late membrane antigens detected by antibodies in human convalescent sera.

Authors:  J M Middeldorp; J Jongsma; T H The
Journal:  J Virol       Date:  1985-04       Impact factor: 5.103

3.  Immunofluorescence for detection of antibodies against human cytomegalovirus-induced membrane antigens.

Authors:  J M Middeldorp; J Jongsma; T H The
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

4.  Immunogenic cells in the regional lymph nodes after painting with the contact sensitizers picryl chloride and oxazolone: evidence for the presence of IgM antibody on their surface.

Authors:  G L Asherson; V Colizzi; M C Watkins
Journal:  Immunology       Date:  1983-03       Impact factor: 7.397

5.  Immunoglobulin M to cytomegalovirus in primary and reactivation infections in renal transplant recipients.

Authors:  S Chou; D Y Kim; K M Scott; D L Sewell
Journal:  J Clin Microbiol       Date:  1987-01       Impact factor: 5.948

6.  Immunoglobulin M antibodies detected by enzyme-linked immunosorbent assay and radioimmunoassay in the diagnosis of cytomegalovirus infections in pregnant women and newborn infants.

Authors:  S Stagno; M K Tinker; C Elrod; D A Fuccillo; G Cloud; A J O'Beirne
Journal:  J Clin Microbiol       Date:  1985-06       Impact factor: 5.948

7.  Maintenance of cytomegalovirus (CMV) latency and host immune responses of long term renal allograft survivors. I. Prolonged suppression of in vitro lymphocyte responses against CMV infected fibroblasts related to previous secondary CMV infection.

Authors:  H W Roenhorst; J M Middeldorp; J M Beelen; J Schirm; A M Tegzess; T H The
Journal:  Clin Exp Immunol       Date:  1985-03       Impact factor: 4.330

Review 8.  Acquisition of cytomegalovirus infection: an update.

Authors:  B A Forbes
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

9.  Antibody response to recombinant lambda gt11 fusion proteins in cytomegalovirus infection.

Authors:  M P Landini; T Lazzarotto; A Ripalti; M X Guan; M La Placa
Journal:  J Clin Microbiol       Date:  1989-10       Impact factor: 5.948

10.  Increased IgM and IgM immune complex-like material in the circulation of renal transplant recipients with primary cytomegalovirus infections.

Authors:  W M Baldwin; A van Es; R M Valentijn; G W van Gemert; M R Daha; L A Vanes
Journal:  Clin Exp Immunol       Date:  1982-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.